News
Among these, biotech giant Bristol Myers Squibb BMY was down after a late-stage study on cardiovascular drug Camzyos failed. On the other hand, Verve Therapeutics VERV skyrocketed on positive data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback